Mutant huntingtin can paradoxically protect neurons from death

Cell Death and Differentiation

Volumn 15, Issue 3, 2008, Pages 435-442

  Zuchner, T ^a   Brundin, P ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CASEIN KINASE; CASPASE 3; CASPASE 6; CYSTATHIONINE BETA SYNTHASE; ENDOPHILIN; GLUTAMATE RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NUCLEAR RECEPTOR COREPRESSOR; POSTSYNAPTIC DENSITY PROTEIN 95; PROLINE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; QUINOLINIC ACID; RAS PROTEIN;

AKINESIA; AMINO ACID SEQUENCE; APOPTOSIS; CELL DEATH; CELL LOSS; CHOREA; CHROMOSOME 4; DISEASE DURATION; EXCITOTOXICITY; EXON; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUNTINGTON CHOREA; IMMOBILIZATION; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; WILD TYPE;

ANIMALS; BRAIN; CELL DEATH; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUTAMATE;

MUS MUSCULUS;

EID: 39449105711     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402261     Document Type: Review

References (53)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
3. Vonsattel JP, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol 1985; 44: 559-577.
4. Ferrante RJ, Beal MF, Richardson Jr EP, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985; 230: 561-563.
5. Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR et al Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci USA 1995; 92: 8710-8714.
6. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J et al. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997; 42: 604-612.
7. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 2004; 24: 269-281.
8. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004; 5: 958-963.
9. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
10. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003; 34: 325-337.
11. Schwarcz R, Whetsell Jr WO, Mangano RM. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316-318.
12. Hansson O, Petersen A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 1999; 96: 8727-8732.
13. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001; 14: 1492-1504.
14. Snell RO, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993; 4 393-397.
15. Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004; 127: 505-516.
16. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005; 102: 11402-11487.
17. Leavitt BR, Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK et al. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006; 96: 1121-1129.
18. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-1191.
19. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitoxicity in a mouse model of Huntington's disease. Neuron 2002; 33: 849-860.
20. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR et al. Striatal neurons apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 2006; 21: 392-403.
21. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 1999; 157: 1-18.
22. Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem 2001; 78: 694-703.
23. Petersen A, Hansson O, Puschban Z, Sapp E, Romero N, Castilho RF et al. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur J Neurosci 2001; 14: 1425-1435.
24. Hickey MA, Morton AJ. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J Neurochem 2000; 75: 2163-2171.
25. Morton AJ, Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull 2000; 52: 51-59.
26. MacGibbon GA, Hamilton LC, Crocker SF, Costain WJ, Murphy KM, Robertson HA et al. Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. J Neurosci Res 2002; 67: 372-378.
27. Schiefer J, Alberty A, Dose T, Oliva S, Noth J, Kosinski CM. Huntington's disease transgenic mice are resistant to global cerebral ischemia. Neurosci Lett 2002; 334: 99-102.
28. Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat Genet 2005; 37: 198-204.
29. Sittler A, Walter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 1998; 2: 427-436.
30. Liu YF, Deth RC, Devys D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem 1997; 272: 8121-8124.
31. Steffan JS, Kazantsev A, Spasic-Boskovio O, Greenwald M, Zhu YZ, Gohler H et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000; 97: 6763-6768.
32. Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M. PACSIN 1-interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet 2002; 11: 2547-2558.
33. Sun Y, Savanenin A, Reddy PH, Liu YF. Polyglutemine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 2001; 276: 24713-24718.
34. Boutell JM, Wood JD, Harper PS, Jones AL. Huntingtin interacts with systathionine beta-synthase. Hum Mol Genet 1998; 7: 371-378.
35. Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 2002; 11: 2815-2828.
36. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D et al. HIP-1: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 1997; 6: 487-495.
37. Hattula K, Peranen J. FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis. Curr Biol 2000; 10 1603-1606.
38. Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum Mol Genet 1999; 8: 1647-1655.
39. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R et al The SH2 and SH3 domain-containing protein GRB2 links receptortyrosine kinases to ras signaling. Cell 1992; 70: 431-442.
40. Ellis CMM, McCormick F, Pawson T. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 1990; 343: 377-381.
41. Henkemeyer MAD, Holmyard DP, Puri MC, Mbamula G, Harpal K, Shih TS et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995; 377: 695-701.
42. Lievens JC, Rival T, Iohe M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 2005; 14 713-724.
43. Peterson AA, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P et al. Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death. Brain Res Bull 2001; 56: 331-335.
44. Petersen A, Brundin P. Effects of ciliary neurotrophic factor on excitotoxicity and calcium-ionophore A23187-induced cell death in cultured embryonic striatal neurons. Exp Neurol 1999; 160: 402-412.
45. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M et al 'Ischemic tolerance phenomenon found in the brain. Brain Res 1990; 528: 21-24.
46. Bond A, Lodge D, Hicks CA, Ward MA, O'Neill MJ. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus. Eur J Pharmacol 1999; 380: 91-99.
47. Grabb MC, Choi DW. Ischemic tolerance in murine cortical cell culture: critical role for NMDA receptors. J Neurosci 1999; 19: 1657-1662.
48. Kato H, Liu Y, Araki T, Kogure K. MK-801, but not anisomycin, inhibits the inducton of tolerance to ischemia in the gerbil hippocampus. Neurosci Lett 1992; 139: 118-121.
49. Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D et al Oral uridine pro-drug PN401 is neuroprotective in the R8/2 and N171-82O mouse models of Huntington's disease. Neurobiol Dis 2006; 24: 455-465.
50. Dedeoglu A, Ferrante RJ, Andreassen OA, Dillmann WH, Beal MF. Mise overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Exp Neurol 2002; 176: 262-265.
51. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2006; 103: 9345-9350.
52. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 2005; 102: 18189-18194.
53. Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J et al. Chemotherapy for the brain: The antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 2004; 24: 10335-10342.